Philip PA - Search Results

1

F-BOX proteins in cancer cachexia and muscle wasting: Emerging regulators and therapeutic opportunities.

Sukari A, Muqbil I, Mohammad RM, Philip PA, Azmi AS. Sukari A, et al. Among authors: philip pa. Semin Cancer Biol. 2016 Feb;36:95-104. doi: 10.1016/j.semcancer.2016.01.002. Epub 2016 Jan 21. Semin Cancer Biol. 2016. PMID: 26804424 Free PMC article. Review.

2

Expression of inflammatory modulator COX-2 in pancreatic ductal adenocarcinoma and its relationship to pathologic and clinical parameters.

Merati K, said Siadaty M, Andea A, Sarkar F, Ben-Josef E, Mohammad R, Philip P, Shields AF, Vaitkevicius V, Grignon DJ, Adsay NV. Merati K, et al. Am J Clin Oncol. 2001 Oct;24(5):447-52. doi: 10.1097/00000421-200110000-00007. Am J Clin Oncol. 2001. PMID: 11586094

3

Bryostatin 1 induces differentiation and potentiates the antitumor effect of Auristatin PE in a human pancreatic tumor (PANC-1) xenograft model.

Mohammad RM, Adsay NV, Philip PA, Pettit GR, Vaitkevicius VK, Sarkar FH. Mohammad RM, et al. Among authors: philip pa. Anticancer Drugs. 2001 Oct;12(9):735-40. doi: 10.1097/00001813-200110000-00005. Anticancer Drugs. 2001. PMID: 11593055

4

MDM2 inhibitor MI-319 in combination with cisplatin is an effective treatment for pancreatic cancer independent of p53 function.

Azmi AS, Aboukameel A, Banerjee S, Wang Z, Mohammad M, Wu J, Wang S, Yang D, Philip PA, Sarkar FH, Mohammad RM. Azmi AS, et al. Among authors: philip pa. Eur J Cancer. 2010 Apr;46(6):1122-31. doi: 10.1016/j.ejca.2010.01.015. Epub 2010 Feb 13. Eur J Cancer. 2010. PMID: 20156675 Free PMC article.

5

Reactivation of p53 by novel MDM2 inhibitors: implications for pancreatic cancer therapy.

Azmi AS, Philip PA, Aboukameel A, Wang Z, Banerjee S, Zafar SF, Goustin AS, Almhanna K, Yang D, Sarkar FH, Mohammad RM. Azmi AS, et al. Among authors: philip pa. Curr Cancer Drug Targets. 2010 May;10(3):319-31. doi: 10.2174/156800910791190229. Curr Cancer Drug Targets. 2010. PMID: 20370686 Free PMC article.

6

MDM2 inhibitors for pancreatic cancer therapy.

Azmi AS, Philip PA, Almhanna K, Beck FW, Sarkar FH, Mohammad RM. Azmi AS, et al. Among authors: philip pa. Mini Rev Med Chem. 2010 Jun;10(6):518-26. doi: 10.2174/138955710791384054. Mini Rev Med Chem. 2010. PMID: 20377522 Review.

7

Structure-activity studies on therapeutic potential of Thymoquinone analogs in pancreatic cancer.

Banerjee S, Azmi AS, Padhye S, Singh MW, Baruah JB, Philip PA, Sarkar FH, Mohammad RM. Banerjee S, et al. Among authors: philip pa. Pharm Res. 2010 Jun;27(6):1146-58. doi: 10.1007/s11095-010-0145-3. Epub 2010 Apr 27. Pharm Res. 2010. PMID: 20422266 Free PMC article.

8

PAR-4 as a possible new target for pancreatic cancer therapy.

Azmi AS, Philip PA, Zafar SF, Sarkar FH, Mohammad RM. Azmi AS, et al. Among authors: philip pa. Expert Opin Ther Targets. 2010 Jun;14(6):611-20. doi: 10.1517/14728222.2010.487066. Expert Opin Ther Targets. 2010. PMID: 20426700 Free PMC article. Review.

9

Emerging Bcl-2 inhibitors for the treatment of cancer.

Azmi AS, Wang Z, Philip PA, Mohammad RM, Sarkar FH. Azmi AS, et al. Among authors: philip pa. Expert Opin Emerg Drugs. 2011 Mar;16(1):59-70. doi: 10.1517/14728214.2010.515210. Epub 2010 Sep 3. Expert Opin Emerg Drugs. 2011. PMID: 20812891 Free PMC article. Review.

10

MI-219-zinc combination: a new paradigm in MDM2 inhibitor-based therapy.

Azmi AS, Philip PA, Beck FW, Wang Z, Banerjee S, Wang S, Yang D, Sarkar FH, Mohammad RM. Azmi AS, et al. Among authors: philip pa. Oncogene. 2011 Jan 6;30(1):117-26. doi: 10.1038/onc.2010.403. Epub 2010 Sep 6. Oncogene. 2011. PMID: 20818437 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

371 results

Search Page

Filters